Treating the Primary in High vs Low Volume Hormone Sensitive Disease

Imaging Modalities to Treat Node-Positive Disease

The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer

Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective

State-of-the-industry video lectures by leading urology experts
Featured Videos

Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.

Peyronie's disease (PD) can affect men of all ages and is associated with penile pain as well as curvature and erectile dysfunction. Treatment modalities for PD include conservative, less invasive and surgical treatments.

Choice of treatment depends on the disease's phase. Injection of collagenase Clostridium histolyticum (CCH) is only the Food and Drug Administration approved treatment for the management of the chronic phase of the disease. Only a few limited studies have evaluated its potential benefits during the acute phase.

To evaluate the current evidence on the use of injectable CCH during the acute or active phase of PD.

We performed a PubMed database search for articles published between 2015 and 2018 that investigated the use of CCH for the management of the acute phase of PD. Search keywords included "Peyronie's disease", "collagenase Clostridium histolyticum", and "acute phase".

Changes in penile curvature after treatment with injectable CCH.

Mean curvature decrease ranged between 15.8° and 22.6° corresponding to 27.4-37.4% decrease from baseline after 2.5-4 cycles, corresponding to 5-8 injections, of CCH treatment in patients during the acute phase of PD.

Intralesional CCH injection therapy during the acute phase of PD can be both safe and effective and clinically significant improvements in penile curvature may be achieved. Larger multi-institutional studies are, however, still needed to confirm these results and validate this additional indication for CCH.

World journal of urology. 2019 May 15 [Epub ahead of print]

Farouk M El-Khatib, Maxwell Towe, Faysal A Yafi

Department of Urology, University of California Irvine, 333 The City Blvd W, Suite 2100, Orange, CA, 92868, USA., Department of Urology, University of California Irvine, 333 The City Blvd W, Suite 2100, Orange, CA, 92868, USA. .

Conference Coverage
Recent data from conferences worldwide
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
  • 2019 World Congress / May 1-3 / Liverpool, United Kingdom
  • 2019 Symposium / April 1-4 / Ottawa, ON
Publications focusing on urologic cancer treatments through original manuscripts

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.